Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research development manufacture marketing and out-licensing of pharmaceutical products in Japan the United States Europe Canada Latin America Russia rest of Asia and internationally. It offers pharmaceutical products in the areas of gastroenterology rare diseases plasma derived therapies oncology and neuroscience. The company provides its products under the Entyvio Gattex/Revestive Takecab Alofisel Dexilant Natpara Adynovate/Adynovi Takhzyro Livtencity Elaprase Replagal Advate Vpriv Gammagard Liquid/Kiovig Hyqvia Cuvitru Exkivity Velcade Leuplin/Enantone Adcetris Vyvansese Trintellix and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd. ZEDIRA GmbH and Dr. Falk Pharma GmbH as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics Code Bio Immusoft Poseida Therapeutics Selecta Biosciences BridGene Biosciences Skyhawk Therapeutics and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo Japan.